News from inovio pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 07, 2023, 08:00 ET INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Aug 29, 2023, 08:00 ET INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Aug 09, 2023, 16:05 ET INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update

Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation...

Aug 04, 2023, 08:00 ET INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Jul 26, 2023, 09:32 ET INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Jun 01, 2023, 08:00 ET INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

May 25, 2023, 08:00 ET INOVIO to Present at the 2023 Jefferies Healthcare Conference

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

May 23, 2023, 16:13 ET INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

May 10, 2023, 16:05 ET INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights

Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed...

May 08, 2023, 08:00 ET New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

May 05, 2023, 08:00 ET INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Apr 28, 2023, 08:00 ET INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Apr 27, 2023, 08:00 ET INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Apr 26, 2023, 08:00 ET European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Apr 17, 2023, 08:00 ET Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Apr 12, 2023, 08:00 ET INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Apr 03, 2023, 08:00 ET INOVIO Reports Inducement Grant Under Inducement Plan

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Mar 03, 2023, 08:00 ET INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Mar 01, 2023, 16:05 ET INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial...

Feb 16, 2023, 08:00 ET INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 ...

Feb 15, 2023, 08:00 ET INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Feb 03, 2023, 08:00 ET INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Feb 02, 2023, 08:00 ET INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Jan 31, 2023, 08:00 ET INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

Nov 17, 2022, 16:30 ET INOVIO Provides an Update on Lassa Fever and MERS Programs

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases,...